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Abstract 
Background: A core outcome set (COS; an agreed, minimum set of outcomes) was needed 
to address the heterogeneous measurement of outcomes in aphasia treatment research and to 
facilitate the production of transparent, meaningful and efficient outcome data.  
Objective: The Research Outcome Measurement in Aphasia (ROMA) consensus statement 
provides evidence-based recommendations for the measurement of outcomes for adults with 
post-stroke aphasia within phase I-IV aphasia treatment studies. 
Methods: This statement was informed by a four-year program of research which comprised 
investigation of stakeholder-important outcomes using consensus processes, a scoping review 
of aphasia outcome measurement instruments, and an international consensus meeting.  This 
paper provides an overview of this process and presents the results and recommendations 
arising from the international consensus meeting.  
Results: Five essential outcome constructs were identified: Language, communication, 
patient-reported satisfaction with treatment and impact of treatment, emotional wellbeing, 
and quality of life. Consensus was reached for the following measurement instruments: 
Language: The Western Aphasia Battery Revised (WAB-R) (74% consensus); emotional 
well-being: General Health Questionnaire (GHQ)-12 (83% consensus); quality of life: Stroke 
and Aphasia Quality of Life Scale (SAQOL-39) (96% consensus). Consensus was unable to 
be reached for measures of communication (where multiple measures exist) or patient-
reported satisfaction with treatment or impact of treatment (where no measures exist).   
Discussion: Harmonisation of the ROMA COS with other core outcome initiatives in stroke 
rehabilitation is discussed.  Ongoing research and consensus processes are outlined.  
Conclusion: The WAB-R, GHQ-12, and SAQOL-39 are recommended to be routinely 
included within phase I-IV aphasia treatment studies. This consensus statement has been 
endorsed by the Collaboration of Aphasia Trialists, the British Aphasiology Society, the 
German Society for Aphasia Research and Therapy, and the Royal College of Speech 
Language Therapists. 
 
A core outcome set for aphasia treatment research: the ROMA consensus statement 
The Research Outcome Measurement in Aphasia (ROMA) consensus statement provides 
recommendations for a core outcome set (COS) for use in aphasia treatment studies. A COS 
is a minimum set of outcomes that should be measured and reported in research trials of a 
specific health condition or population (1). The use of a COS does not preclude the 
measurement of additional outcomes, but rather represents the minimum outcomes that 
should be collected and reported (2). A COS for aphasia was developed in response to a trend 
of heterogeneous outcome measurement in research and the merits of this initiative were 
debated in a published forum in 2014 (3-7). The ROMA consensus statement was informed 
by a four-year program of research in three phases: (1) investigation of stakeholder-important 
outcomes using consensus processes (8-11); (2) a scoping review to identify aphasia outcome 
measurement instruments (OMIs) and their psychometric properties (12); and (3) an 
international consensus meeting (results reported herein). The ROMA COS is intended to 
complement other existing and ongoing initiatives to standardise the measurement of stroke 
recovery (13-15).  
Objective  
The ROMA consensus statement provides evidence-based recommendations for the 
measurement of outcomes for adults with post-stroke aphasia within phase I-IV aphasia 
treatment studies. 
Target users 
The primary users of this consensus statement will be researchers involved in the design and 
conduct of aphasia treatment studies. 
 
Methods 
The research methods are based on the recommendations of the Core Outcome Measures in 
Effectiveness Trials (COMET) Initiative (2, 16) and are reported in alignment with the COS-
STAR (Core Outcome Set-STAndards for Reporting) statement (17). The World Health 
Organization International Classification of Functioning, Disability and Health (ICF) (18) has 
been used as a conceptual framework and classification tool. This project is registered with 
the COMET Initiative (http://www.comet-initiative.org/studies/details/287).  
Stage 1: Identification of Core Outcome Constructs 
Outcome constructs were derived from three separate stakeholder consensus studies 
conducted with: people with aphasia and their families (9); aphasia clinicians and managers 
(8); and aphasia researchers (10).  Outcomes prioritised by stakeholder groups were 
integrated using the framework of the ICF (19). Essential constructs were identified as: 
Language, communication, patient-reported satisfaction with treatment and impact of 
treatment, emotional wellbeing, and quality of life (11). 
Stage 2: Identification of Outcome Measurement Instruments 
A scoping review was conducted to identify OMIs which have been validated with people 
with aphasia. Primary searches were run using PUBMED, EMBASE, and CINAHL databases 
on 10 November 2015. The search strategy incorporated filters developed for the 
identification of studies reporting the measurement properties of health OMIs (see 20 and 
supplementary file). Inclusion criteria required that studies focused on the psychometric 
properties of measurement instrument and included participants with aphasia or stroke 
patients where participants with aphasia were not specifically excluded. Studies reporting 
measurement instruments which primarily measure neurological function associated with, but 
not central to aphasia: e.g., consciousness; health; motor speech; cognition; memory; were 
excluded. Secondary searches were conducted for each OMI identified in the first search. In 
total, 184 references for 79 measurement instruments were identified (12). No measures of 
patient-reported treatment impact or patient-reported satisfaction were identified through this 
search.  
Stage 3. Formation of Consensus Panel  
Researchers who participated in the first phase of this project (n=80) (10) were invited to 
participate in the final consensus meeting. These researchers were purposively sampled from 
researchers whose trials were included with the Cochrane Collaboration review of "Speech 
and language therapy for aphasia following stroke"(21) and the 100 most highly published 
aphasia treatment researchers in the Web of Science database. In total, 23 researchers 
participated in a consensus meeting in London, UK (December, 2016).  Panel members were 
experienced researchers with expertise in: the design and conduct of aphasia trials; 
measurement instrument development and testing; and clinical guidelines development (see 
table 1 and supplementary table 1). Authors Wallace, Worrall, Le Dorze and T. Rose 
facilitated the COS development process and did not participate in COS voting. 
Table 1 
Characteristics of researchers who participated in the international consensus panel 
(n=23) 
Panel Characteristics n (%) 
Country  
    United Kingdom 9 (39) 
    United States of America 6 (26) 
    Australia 3 (13) 
    Canada 2 (9) 
    Germany 1 (4) 
    Sweden 1 (4) 
    Ireland 1 (4) 
ICF component to which their own research relates (panel 
members could nominate more than one component) 
 
   Body functions 16 
   Activity/Participation 21 
   Environmental factors 10 
   Personal factors 15 
   Quality of life* 12 
Number of treatment studies published by participants  
   1 2 
   2-5 8 
   6-10 4 
   more than 10 7 
   not specified 2 
*nb. Quality of life is not defined as a component of the ICF 
 
Stage 4. International Consensus Meeting 
Ethical approval for the consensus meeting was gained from the Behavioural and Social 
Sciences Ethical Review Committee at The University of Queensland, Australia. The 
following process was used:  
Prior to meeting 
(1) Panel members generated consensus-based criteria to enable an initial reduction of OMIs 
(see table 2).  
(2) The consensus-based criteria were applied to the list of OMIs identified in the stage 2 
scoping review (n=79) to produce a short-list (n=50) (see supplementary table 2).   
(3) Panel members generated consensus-based feasibility criteria (see table 3). 
(4) The short-listed OMIs (see supplementary table 2) were assigned to panel members, who 
reviewed OMI feasibility and measurement properties prior to the consensus meeting.   
 
 
During the meeting 
(1) Panel members engaged in a whole-group discussion using an iterative process to apply 
feasibility criteria and eliminate OMIs.  
(2) Panel members divided to smaller groups to review the measurement properties for each 
OMI in the target population (people with aphasia). Properties considered included: 
acceptability/feasibility of use with people with aphasia, reliability (test-retest, inter- and 
intra- as applicable), construct validity, and sensitivity to change.  
(3) Each small group recommended two OMIs for voting. Panel members voted YES/NO for 
each OMI in a closed voting process with consensus defined a priori as agreement on 
each OMI for each outcome construct by ≥ 70% of meeting participants, as suggested by 
the COMET initiative and GRADE working group (2). Potential conflicts of interest were 
managed through agreement that authors of OMIs under consideration could not 
participate in voting for that construct area.   
Table 2 
Criteria for initial reduction of outcome measurement instruments 
Measures were excluded if: 
1. The purpose of the measurement instrument was to screen for the presence of aphasia, 
rather than to measure outcomes. 
2. The measurement instrument was published more than thirty years ago (i.e., prior to 
1986) without subsequent revision and/or was not in current use. 
3. The measurement instrument targeted only one severity level of aphasia.  
4. For measures of language: the measurement instrument did not assess all modalities of 
language (e.g. reading only, writing only, comprehension only, verbal output only).  
 
 
 
Table 3 
Feasibility criteria  
1. Availability in different languages or ease of translation/adaptation. 
2. Cost. 
3. Burden to respondents or researchers (ease of administration, length of outcome 
measurement instrument, completion time). 
4. Ease of score calculation and provision of an aggregate score. 
 
 
Results  
After compilation of votes, panel members reached consensus for measures of language, 
emotional wellbeing, and quality of life (refer to table 4). A consensus of ≥ 70% was not 
reached for a measure of communication.  Inability to gain consensus on a measure of 
communication may relate to the multi-factorial nature of this construct, as well a lack of 
understanding and consensus around how ‘effective communication’ is best operationalised 
in treatment research.  
 
Table 4 
Results of final voting to decide core outcome measurement instruments 
Construct Measure* Votes for 
inclusion 
Language The Western Aphasia Battery Revised (WAB-R)  74% (n=17) 
 The Comprehensive Aphasia Test (CAT) 22% (n=5) 
 Neither 4% (n=1) 
Communication The Scenario Test 57% (n=13) 
 The Communication Effectiveness Index (CETI) 39% (n=9) 
 Abstained 4% (n=1) 
Emotional well-
being 
General Health Questionnaire (GHQ)-12  83% (n=19) 
 Stroke Aphasic Depression Questionnaire (SADQ) 17% (n=4) 
Quality of life Stroke and Aphasia Quality of Life Scale (SAQOL-
39)  
96% (n=22) 
 Burden of Stroke Scale (BOSS) 0% (n=0) 
 Abstained 4% (n=1) 
Bolded figures indicate consensus criteria (≥70%) reached and OMI included in COS 
*Refer to supplementary tables 3 & 4 for OMI characteristics, properties and references. 
 
Recommendations 
It is recommended that the WAB-R, GHQ-12 and SAQOL-39 be included as core outcome 
measurement instruments in phase I-IV aphasia treatment studies for adults with post-stroke 
aphasia. These outcome measurement instruments and their psychometric properties are 
described in supplementary tables 3 & 4.  
 
Discussion 
The importance of implementing standardised approaches to outcome measurement in 
research trials is increasing acknowledged. In the field of stroke rehabilitation, the Stroke 
Recovery and Rehabilitation Roundtable (SRRR) (13) have provided consensus-based core 
recommendations for the measurement of sensorimotor recovery after stroke. Other 
initiatives have addressed the measurement of stroke outcomes in clinical practice (15) and 
there are ongoing works to standardise measures in arm rehabilitation trials after stroke (14). 
The ROMA COS has sought to provide recommendations specifically for the measurement of 
aphasia recovery post-stroke. Accordingly, some frequently used measures of global 
disability and health-related quality of life (e.g., EQ-5D) which do not contain 
communication-specific items or which have not been validated with stroke survivors with 
aphasia were not considered within this process. The ROMA COS seeks to harmonise with 
other existing stroke rehabilitation initiatives in addressing the need for standardised 
approaches to research trial outcomes measurement and its supplementary use may therefore 
be considered in any stroke study where people with aphasia are included.   
 
Future Directions 
The ROMA COS will be reviewed biennially. The next consensus meeting will focus on 
measures of communication and consider the development of measures of patient-reported 
satisfaction with treatment / impact of treatment. Factors relating to international COS 
implementation will be considered. New publications, initiatives and user feedback will also 
be considered in each review to: align this COS with other COSs; consider new OMIs; and to 
review the choice of OMIs based on user feedback. 
 
Limitations 
Participants in the international consensus meeting were predominately from English 
speaking countries. This may have impacted the consensus process and findings. Future 
meetings will seek to increase the diversity of participants with respect to cultural and 
linguistic background.  
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Supplementary Table 2 
OMIs (n=50) identified in scoping review and retained following application of the 
consensus-based criteria 
Construct Outcome measurement instrument 
L
an
g
u
ag
e 
 The Comprehensive Aphasia Test (CAT) (1) 
 The Western Aphasia Battery Revised (WAB-R) (AQ+LQ) (2) 
 Therapy Outcome Measures (TOM) (3-5) 
 The Aphasia Checklist (ACL) (6) 
 Aachen Aphasia Test (AAT) (7) 
 Aphasia Language Assessment Test (ALA) (8) 
 The Thai Aphasia Language Performance Scales (ALPS) (9) 
 Bilingual Aphasia Test (BAT) (10) 
 The Boston Diagnostic Aphasia Examination  (BDAE) (11) 
 Ege Aphasia Test (12) 
 Kentucky Aphasia Test (KAT) (13) 
 Montreal-Toulouse Language Assessment Battery (MTL) (14) 
 The Norsk Grunntest for Afasi  (NGTA) (15) 
E
m
o
ti
o
n
al
 w
el
l-
b
ei
n
g
 
 Communication Confidence Rating Scale for Aphasia (CCRSA) (16) 
 Hospital Anxiety and Depression Scale (HADS) (17) 
 Montgomery-Asberg Depression Rating Scale (MADRS) (18) 
 Geriatric Depression Scale (GDS) 15 item / 30 item (19, 20) 
 Warwick and Edinburgh mental well-being scale (21) 
 Geriatric anxiety scale (22) 
 Stroke and Aphasia (SAD) Scale (23) 
 Signs of Depression Scale (SODS) (24) 
 Stroke Aphasic Depression Questionnaire (SADQ) (25) 
 Visual Analogue Self-Esteem Scale (VASES) (26) 
 Centre for Epidemiology Depression Scale –Revised (27) 
 General Health Questionnaire (GHQ) 12 item (28) 
 Therapy Outcome Measures (TOM) (29-31) 
 Patient Health Questionnaire 2 item / 9 item  (32, 33) 
 Visual Analogue Mood Scale (VAMS) (34) 
C
o
m
m
u
n
ic
at
io
n
 
 Aphasia Communication Outcome Measure (ACOM) (35)  
 American Speech-Language and Hearing Association Functional Assessment 
of Communication Skills for Adults (ASHA-FACS) (36) 
 Amsterdam-Nijmegen Everyday Language Test (ANELT) (37) 
 The Communication Activity Log (CAL) (38) 
 The Communication Outcome After Stroke (COAST) (39) 
 The Communicative Activities Checklist (COMACT) (40) 
 The Social Activities Checklist (SOCACT) (40) 
 The Communication Disability Profile (CDP) (41) 
 The Communication Effectiveness Index (CETI) (42) 
 Community Integration Questionnaire (CIQ-R) (43) 
 Communication Activities of Daily Living (CADL) (44) 
 The Functional Outcome Questionnaire for Aphasia (FOQ-A) (45) 
 Measure of participation in conversation (MPC) (46) 
 The Scenario Test (47) 
 The Speech Questionnaire (48) 
 Therapy Outcome Measures (TOM) (29-31) 
 The Communication Participation Item Bank (49) 
Q
u
al
it
y
 o
f 
L
if
e 
 Aachen Life Quality Inventory (ALQI) (50) 
 Burden of Stroke Scale (BOSS) (51) 
 The Newcastle Stroke-Specific Quality of Life Measure (NEWSQOL) (52) 
 Short Form 36 Health Survey (SF-36)  (53) 
 Stroke and Aphasia Quality of Life Scale (SAQOL-39) (54, 55) 
 
 
Supplementary Table 3 
Description of recommended outcome measurement instruments 
 Outcome 
instrument and 
abbreviation 
Development / 
alternate versions 
Aims/instrument 
description 
Number 
of items 
Duration Scoring system Training Cost*/ 
availability 
Language 
translations 
Western 
Aphasia 
Battery 
Revised 
(WAB-R) (2) 
Developed by 
Kertesz in 1979 
based on the 
original format of 
the Boston 
Diagnostic 
Aphasia 
Examination (56). 
 
Revisions 
published in 1982 
and 2006 (WAB-
R): 
Supplemental 
tasks, revision of 
15 items and 
testing materials 
(e.g. spiral-bound 
stimulus book 
replacing loose 
stimulus cards), as 
well as revised 
directions and 
scoring guidelines 
for clarity.  
 
The WAB-R also 
includes a bedside 
screening tool 
(Bedside WAB-
R). 
Primary: Assessment 
of linguistic skills in 
aphasia: 
1. Spontaneous speech 
2. Auditory verbal 
comprehension 
3. Repetition 
4. Naming and word 
finding 
5. Reading 
6. Writing 
7. Apraxia 
8. Constructional, 
visuospatial, and 
calculation tasks 
9. Supplemental 
writing and reading 
tasks: reading and 
writing of irregular 
and non-words 
(WAB-R only) 
Secondary: Assessment 
of non-linguistic skills 
in aphasia: 
drawing, block design, 
calculation, and praxis 
1. Additional aims: 
Classification of 8 
aphasia types: 
Global, Broca’s, 
Transcortical motor, 
Wernicke’s, 
>300  Bedside WAB-
R: 15 min 
(comprises half 
of the items of 
WAB-R Part 1) 
 Part 1: 30-45 
min 
 Part 2: 45-60 
min 
 Aphasia Quotient 
(AQ): a weighted 
average of the 
WAB spoken 
language subtest 
scores.  
 Cortical Quotient 
(CQ): a weighted 
average of both 
the language and 
non-language 
subtest scores. 
 The Language 
Quotient (LQ): 
reflects auditory 
comprehension, 
oral expression, 
reading, and 
writing 
performance. 
Administration: 
“some training” 
required 
according to 
developers. 
Scoring 
procedures 
require training. 
Testing 
materials: 
+++  
 
Available 
from: 
https://ww
w.pearsonc
linical.com  
Cantonese (57)  
Korean (58) 
Bangla (59) 
Tagalog (60)  
Brazilian 
Portuguese (61) 
Japanese (62) 
Hungarian 
French 
Turkish (63) 
Hebrew 
Spanish (64) 
 
 
Transcortical 
sensory, Mixed 
transcortical, 
Conduction, and 
Anomic 
2. Assessment of 
aphasia severity 
3. Used to determine 
the location of the 
lesion 
Stroke and 
Aphasia 
Quality of 
Life Scale 
(SAQOL-39; 
SAQOL-39g) 
(54, 55) 
The SAQOL-
39 is the short 
form of the 
SAQOL (53 
items), which 
is itself an 
adaptation of 
the SS-QOL 
(Stroke-
specific 
Quality of life 
scale). 
The SAQOL-
39 was 
originally 
tested in 
people with 
chronic 
aphasia (the 
measure had 
four domains: 
physical, 
psychosocial 
communicatio
n, energy. 
Interview-administered 
self-report measure, 
SAQOL-39 comprises 
39 questions, in four 
quality of life (QoL) 
domains: 
 
1. Physical (17 items)  
2. Communication (7 
items) 
3. Psychosocial (11 
items) 
4. Energy (4 items) 
 
SAQOL 39g comprises 
the same 39 questions, 
in three quality of life 
(QoL) domains: 
 
1. Physical (16 items)  
2. Communication (7 
items) 
3. Psychosocial (16 
items) 
 
Timeframe for all 
questions is the past 
week 
 
39  15-20 min 
(depending on 
severity of 
aphasia) 
 Twenty-one of 
the items ask the 
respondents how 
much trouble 
they have had 
with activities 
(e.g., getting 
dressed, 
speaking). The 
response format 
for these 
questions is a 5-
point scale that 
varies from 
1=‘couldn’t do it 
at all’ to 5=‘no 
trouble at all’. 
The rest of the 
items (18) ask 
about feelings 
(e.g., ‘did you 
feel irritable?’) 
and other 
activities (e.g., 
‘did you see your 
friends less often 
than you would 
like?’). Their 
response format 
Administration: 
Guidance is 
provided in 
administration 
guidelines. 
Administrators 
need to have 
skills in 
communicating 
with people 
with aphasia 
Scoring 
procedures: no 
training required 
Free. 
 
Available 
from: 
https://blog
s.city.ac.uk
/cityaccess
/saqol-
description
/  
Chilean (68) 
Chinese (69) 
Chinese 
mandarin (70) 
Dutch (71) 
Greek (72, 73)  
Hindi (74)  
Italian (75) (76) 
Japanese (77) 
Kannada (78) 
Korean (79) 
Malayalam (80) 
Persian (81) 
Portuguese (82) 
Spanish (83) 
Turkish (84) 
 
Testing the 
SAQOL-39 in 
generic stroke 
population (n=87) 
resulted in the 
SAQOL-39g, 
which has the 
same items as the 
SAQOL-39 but 
three domains (all 
energy items 
groups with the 
psychosocial 
domain).  
 
There are 
alternative forms 
for proxy 
administration 
(65, 66) and for 
postal and 
telephone 
administration 
(67) 
Multi-modal 
presentation, i.e., 
patients can both read 
and listen to the 
questions. People with 
expressive aphasia can 
point to their responses 
instead of verbally 
responding. 
varies from 
1=‘definitely 
yes’ to 
5=‘definitely 
no’. 
 
Calculation of:  
1. total score: mean 
score of all 39 
items 
2. Domain scores: 
mean score of all 
items relating to 
the respective 
domain 
General 
Health 
Questionnaire 
(GHQ) 12 
Developed in 
1972. Current 
version published 
in 2011) 
 
Alternate 
versions: 
 GHQ-60: 60-
item 
questionnaire 
 GHQ-30: a 
short form 
without items 
relating to 
Primary: Screening 
device for identifying 
minor psychiatric 
disorders in the general 
population and within 
community or non-
psychiatric clinical 
settings such as primary 
care or general medical 
out-patients. 
 
12 questions relating to 
symptoms of various 
psychiatric conditions, 
assesses the respondent's 
12 2 min 
administration time 
(in non-language 
impaired samples) 
4-scale response 
options (exact 
wording depends on 
item): 
1. 'better/healthier 
than normal'  
2. 'same as usual'  
3. 'worse/more than 
usual'  
4. ‘much 
worse/more than 
usual' 
Administration: 
no training 
required. 
 
Scoring 
procedures: no 
training 
required. 
Testing 
materials: 
+ 
 
Available 
from: 
https://ww
w.gl-
assessment
.co.uk 
 
Italian (85) 
Arabic (86) 
Turkish (87) 
Persian (88) 
Portuguese (89) 
Kannada (90) 
Hindi (91) 
Spanish (92) 
 
A number of 
other 
unvalidated 
translations are 
available. The 
MAPI Research 
physical 
illness  
 GHQ-28: a 
28 item 
scaled 
version – 
assesses 
somatic 
symptoms, 
anxiety and 
insomnia, 
social 
dysfunction 
and severe 
depression (7 
items for 
each of the 
four scales) 
current state and asks if 
that differs from his or 
her usual state, and is 
therefore sensitive to 
short-term psychiatric 
disorders. 
4 possible methods of 
scoring. GHQ scoring 
(0-0-1-1) is 
advocated by the test 
author. 
 
GHQ-12 yields only 
an overall total score 
(range: 0 to 12 points 
with standard scoring 
procedure). 
 
Trust distributes 
translated 
versions on 
behalf of GL 
Assessment. 
Contact: 
PROinformation
@mapi-trust.org  
 
* Free, + Up to US$100, ++ Up to US$200, +++ > US$200 
  
Supplementary Table 4 
Properties of recommended outcome measurement instruments 
 
 Western Aphasia Battery – Revised (WAB-R)  Stroke and Aphasia Quality of Life Scale (SAQOL-
39/39g) 
General Health Questionnaire (GHQ-12) 
Objectivity  During assessment: Limited because no 
audio recordings of verbal stimulus 
material available 
 During scoring: Limited for spontaneous 
speech and written output subtests 
 During assessment: Moderate (interaction 
between assessor and patient frequently 
required because of physical stroke symptoms 
(arm paresis) and lack of pictorial task 
instructions (written sentences only) 
 During scoring: High 
 During assessment: High if assessor 
does not interact with patient 
 During scoring: High 
Internal 
consistency 
High: Cronbach’s alpha of total score= 0.91 
(93).  
High: Cronbach’s alpha of total score= 0.93; 
Cronbach’s alpha of subscale scores= 0.74–0.94 
(54). 
 
SAQOL-39g: High: Cronbach’s alpha of total 
score= 0.95; Cronbach’s alpha for subscale scores= 
0.92-0.95 (55) 
High (in general population): Cronbach’s 
alpha of total score= 0.79-0.91 (94-96). 
Cronbach’s alpha of subscale scores= 
0.80-0.92.  
 
Test-retest 
reliability* 
Excellent test-retest reliability: r >0.90 
 
Acute stage post stroke:  
 Korean version; (58); 5-day test–retest 
interval (n=20 people with aphasia; 
Aphasia Quotient: r=0.976; Language 
Quotient: r=0.977; Cortical Quotient: 
r=0.920; Spontaneous Speech: r=0.96; 
Auditory Comprehension: r=0.967; 
Repetition: r=0.952; Naming: r=0.934; 
Reading: r=0.986; Writing: r=0.988; 
Praxis, r=0.908; Construction: r=0.922).  
 
Chronic stage post stroke: 
 1 year test–retest interval (97), n=22 
patients, r=0.992 
Good to excellent test-retest reliability ICC=0.89-
0.98 
 
 English version; 2 to 14 days; n=17 people 
with aphasia; ICC=0.98 overall, 0.94–0.98 
subscales (54). 
 English generic stroke version (SAQOL-39g); 
7 ± 4 day test–retest interval; n=18 people with 
stroke/ stroke and aphasia; ICC= 0.96 overall; 
ICC= 0.92–0.98 subscales (55) 
 
Other translated versions: 
 Chilean version; ICC=0.95 (67) 
 Chinese  ICC=0.97(69) 
 Chinese mandarin version; ICC=0.98 (70) 
 Dutch  ICC=0.9 (71) 
 Greek ICC=0.96 (73) 
Acceptable to excellent test-retest 
reliability  
 
 General population: ICC=0.79-0.82 
(100) 
 
 Stroke (inc. aphasia) population using 
GHQ-28:  2 month test-retest 
reliability with a sample of 20 
individuals (r=0.90) (101) 
 6 months to 6.5 test–retest interval (av. 
12-23 months test–retest interval; (93)), 
n=38  patients with chronic aphasia; 
WAB-AQ (r=0.968), WAB-CQ (n=9, 
r=0.895), WAB-LQ subtests: 
Spontaneous Speech – Information 
Content (r=0.947) and Fluency (r=0.941), 
Comprehension (r=0.881), Repetition 
(r=0.970), Naming (r=0.923), Reading 
(n=32; r=0.927) and Writing (n=25; 
r=0.956) and the Construction subtest 
(n=14, r=974). Test-retest reliability was 
adequate for the Praxis subtest (n=18, 
r=0.581). 
 Danish version (98); 3.5 months test–
retest interval; n=19, r=0.96.  
 Cantonese version (99); 12 to 16 months 
test–retest interval; n=16 patients, 
Spontaneous Speech subtest – 
Information, Fluency and total scores 
(r=0.83, 0.94, 0.96 respectively), Naming 
subtest (r=0.91), AQ (r=0.93).  
 Hindi  ICC=0.9 (74) 
 Italian  ICC=0.916 (75) (76) 
 Japanese  ICC=0.97 (77) 
 Kannada  ICC=0.8 (78) 
 Korean  ICC=0.909 (79) 
 Malayalam  ICC=0.91 (80) 
 Persian ICC=0.93 (81) 
 Portuguese  ICC=0.927 (82) 
 Spanish  ICC=0.949 (83) 
 Turkish ICC=0.97 (84) 
 
Responsiveness Sub-/acute phase (up to 1 month post-onset):  
 WAB-LQ: n=50 adults with aphasia 
secondary to acute stroke, who received 
treatment (n=42) or no treatment (n=8). 
Participants assessed at baseline (2-4 
weeks post-onset of aphasia), 3 months, 
and at least 6 months post-baseline. 
Significant main effect for time (F=43.33, 
df=2.96, p<0.0001), significant 
differences in the mean scores for the 
three tests (p<0.01). (102) 
 Very Early Rehabilitation of Speech 
(VERSE) trial; n=20 participants with 
mild-severe aphasia receiving 
intervention (4-5 h/wk for 5 wks) 
achieved 18% greater recovery on the 
Acute to post-acute phase (up to 6 months post-
onset):  
 Generic stroke sample, n=87; people admitted 
to hospital with a first stroke were assessed two 
weeks, three months and six months post 
stroke. Moderate changes (d = 0.35—0.49; 
standardized response mean (SRM) = 0.29—
0.53) from two weeks to six months support 
responsiveness. (55) 
 
Post-acute to chronic (3 months to 1 year) 
 Cohort study of stroke sample with and without 
aphasia, n=78. Effect size r=0.22. MID 
estimated 0.21. (107) 
 
Chronic phase (at least 6 months post-onset):  
Acute to post-acute phase (up to 6 months 
post-onset):  
 Impact of stroke with and without 
aphasia across the first six months, 
n=87 people with stroke or stroke and 
aphasia; psychological distress 
significantly reduced with time on 
GHQ-12 [F (2,140) = 7.1, p=0.001] 
(109) 
 
Chronic phase (at least 6 months post-
onset):  
 Effects of singing in a community 
choir on mood; n=13 people with 
aphasia; 2.8 point reduction in mean 
GHQ-12 score was seen by week 12, 
WAB-AQ compared to the usual care 
group (11 min/week for 3 wks) (103). 
 
Post-acute phase (2-6 months post-onset):  
 See (102) above 
 Prospective longitudinal study with n=75 
participants with aphasia post stroke, 
assessments at 4, 8, 12 and 24 weeks 
post-stroke, significant improvement in 
WAB-AQ across first year post-stroke 
(104) 
 
Chronic phase (at least 6 months post-onset):  
 n=10 participants with chronic aphasia. 
Combination of d-amphetamine, TMS, 
and SLT superior to control intervention 
of placebo with TMS and SLT; Change in 
AQ (from 36.13[18.23] to 38.60[19.33], P 
= 0.04) and LQ (from 32.41[14.93] to 
35.03[15.10], P = 0.02) showed a 
statistically significant increase in the 
active experiment. Comparison of 
proportional changes of AQ and LQ in 
the active experiment with AQ and LQ in 
the placebo experiment showed a 
significant difference (AQ, P = 0.02; LQ, 
P = 0.008)  (105) 
 
Mixed stages 
 n= 50 participants with aphasia (49 
secondary to subacute or chronic stroke).  
Participants’ mean scores improved 
significantly from pre- to post-treatment 
on all WAB subtests, with absolute 
percentages ranging from 6.5% to 13% 
improvement (p<0.01 to p<0.0001) (106). 
 Intensive speech and language therapy 
compared to a waiting list control condition; 
n=156; Verbal communication was 
significantly improved from baseline to post- 
treatment (mean difference 2·61 points [SD 
4·94]; 95% CI 1·49 to 3·72), but  
not from baseline to after treatment deferral (–
0·03 points [4·04]; –0·94 to 0·88; between-
group difference Cohen’s d=0·58; p=0·0004). 
F-value for the main comparison is 12.97 
(df1=1, df2=153), p= 0.0004  (108) 
suggesting a possible reduction in 
adverse mood symptoms that was 
sustained to week 20. (110) 
 Effects of solution-focused brief 
therapy, n=5 people with aphasia, On 
GHQ-12 the mean (SD) score before 
therapy was 4.80 (4.60) [median 
(IQR) = 6.00 (0–9.00)]. This was 
reduced after therapy to a mean (SD) 
score of 2.00 (2.55) 
[median (IQR) = 1.00 (0–4.50)]. The 
effect size was large: Cohen’s d = 
0.79. (111) 
 
Caregivers of people with aphasia:   
 Impact of a psychoeducation program 
on caregivers' burden and stress, n 
=31 caregivers of people with post 
stroke aphasia. Caregivers in the 
immediate treatment group had 
significant reductions in GHQ-12 
measured stress (GHQ mean (SD) 
at baseline =6.26 (5.67), GHQ post 
treatment 3.21 (SD 4.20), =/0.006). 
(112) 
Convergent 
validity 
 Convergent validity in sample of n=15 
people with aphasia (93). Comparison 
 SAQOL-39: Good convergent validity (r=0.55 
to 0.67)(54). Adequate correlation between 
Convergent validity in post-stroke aphasia 
sample:  
with corresponding subtests of the 
Neurosensory Center Comprehensive 
Examination for Aphasia (NCCEA), 
using Pearson correlation coefficients 
o Excellent correlation between: 
WAB Spontaneous Speech and 
NCCEA Description of Use and 
Sentence Construction (r= 
0.817); WAB Comprehension 
and NCCEA Identification by 
Name and Identification by 
Sentence (r= 0.915); WAB 
Repetition and NCCEA Sentence 
Repetition (r= 0.880); WAB 
Naming and NCCEA Visual 
Naming and Word Fluency (r= 
0.904); WAB Reading and 
NCCEA Reading subtests 
(r=0.919); WAB Writing and 
NCCEA Writing subtests 
(r=0.905); and WAB and 
NCCEA total scores (r=0.973).  
o Excellent correlation between 
the WAB-CQ (minus the Praxis 
and Construction subtests) and a 
comparable NCCEA score 
(minus the Tactile Naming-
Right/Left, Articulation, Digit 
Repetition-Forward/Backward 
subtests) (r=0.964). 
 Sample of n=45 people with aphasia. 
Excellent correlation between the WAB 
and the Czech version of the Mississippi 
Aphasia Screening Test (MASTcz) (r= 
0.933) (113) 
GHQ-12 and the SAQOL-39 mean (0.53, 
p<0.01). The physical, communication, and 
energy subscales show good convergent 
validity (r=0.39 to 0.67, r=0.55, r=0.32, 
respectively). The psychosocial subdomain 
shows adequate convergent (r=0.28 to 0.62) 
validity with only 1 correlation lower than 
predicted (r=0.28 with the SSS). Good 
correlations with Frenchay Activities Index 
(FAI) and ASHA Functional Assessment of 
Communication Skills (ASHA-FACS). 
 SAQOL-39g: Good/excellent convergent 
validity for overall scale (r=0.36–0.70); and 
subdomains (r=0.47–0.78) (55), evidenced by 
moderate to high correlations with measures of 
stroke severity (NIHSS), activities of daily 
living (Barthel Index), extended activities of 
daily living (Frenchay Activities Index), 
emotional distress (GHQ-12) and language 
(Frenchay Aphasia Screening Test). 
 Good correlations with SAQOL 
39/SAQOL-39 (English, Greek, and 
Turkish versions).  
 The GHQ-12 demonstrated good 
convergent validity in a sample of 83 
individuals with chronic stroke and 
aphasia, by comparison with the 
SAQOL-39. The study yielded an 
adequate correlation between the 
GHQ-12 and the SAQOL-39 mean 
(0.53, p<0.01). Correlations between 
the GHQ-12 and SAQOL-39 subtests 
were adequate (physical r=0.39, 
energy r=0.32, p<0.01) to excellent 
(psychosocial r=0.62, p<0.01). (54) 
Discriminant 
validity 
 Sample of n=140 people with aphasia. 
Comparison of WAB with Raven’s 
SAQOL-39: Discriminant validity (r = 0.02-0.27) 
(54) 
 
Excellent discriminant validity in Swedish 
population (n=556 patient cases surveyed 
in specialized psychiatric care outpatient 
age and n=556 sex-matched controls). 
Coloured Progressive Matrices scores 
Adequate correlation (r=0.547). 
 Sample of n=66 people with chronic 
aphasia. Discriminant validity of the 
WAB Aphasia Quotient (WAB-AQ) by 
comparison with the Scandinavian Stroke 
Scale (SSS), Barthel Index (BI) and 
Frenchay Activities Index (FAI). 
Excellent correlation between the WAB-
AQ and the SSS (r=0.64), 
adequate correlations between the WAB-
AQ and the BI (r=0.44) and the FAI 
(r=0.50).  
SAQOL-39g:  Good/excellent discriminant validity 
for overall scale and subdomains, evidenced by low 
to moderate correlations with external measures (r 
= 0.03-0.40). (55) 
Individuals using specialized psychiatric 
services and healthy controls (Likert index 
AUC=0.86, GHQ index 
AUC=0.83), and between individuals with 
current disorder from healthy controls 
(Likert index AUC=0.90, GHQ index 
AUC=0.88). (114). 
* Test-retest reliability: 1=perfect reliability; ≥ 0.9=excellent reliability; ≥ 0.8 < 0.9=good reliability; ≥ 0.7 < 0.8=acceptable reliability; ≥ 0.6 < 0.7=questionable reliability; 
≥ 0.5 < 0.6=poor reliability; < 0.5=unacceptable reliability; 0=no reliability. 
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OR intraparticipant[tiab] OR intra-participant[tiab] OR kappa[tiab] OR kappa’s[tiab] OR kappas[tiab] 
OR repeatab*[tiab] OR ((replicab*[tiab] OR repeated[tiab]) AND (measure[tiab] OR measures[tiab] 
OR findings[tiab] OR result[tiab] OR results[tiab] OR test[- tiab] OR tests[tiab])) OR 
generaliza*[tiab] OR generalisa*[tiab] OR concordance[tiab] OR (intraclass[tiab] AND 
correlation*[tiab]) OR discriminative[tiab] OR ‘‘known group’’[tiab] OR factor analysis[tiab] OR 
factor analyses[tiab] OR dimension*[tiab] OR subscale*[tiab] OR (multitrait[tiab] AND scaling[tiab] 
AND (analysis[tiab] OR analyses[tiab])) OR item discriminant[tiab] OR interscale correlation*[tiab] 
OR error[tiab] OR errors[tiab] OR ‘‘individual variability’’[tiab] OR (variability[tiab] AND 
(analysis[tiab] OR values[tiab])) OR (uncertainty[tiab] AND (measurement[tiab] OR 
measuring[tiab])) OR ‘‘standard error of measurement’’[tiab] OR sensitiv*[tiab] OR 
responsive*[tiab] OR ((minimal[tiab] OR minimally[tiab] OR clinical[tiab] OR clinically[tiab]) AND 
(important[tiab] OR significant[tiab] OR detectable[tiab]) AND (change[tiab] OR difference[tiab])) 
OR (small*[tiab] AND (real[tiab] OR detectable[tiab]) AND (change[tiab] OR difference[tiab])) OR 
meaningful change [tiab] OR ‘‘ceiling effect’’[tiab] OR ‘‘floor effect’’[tiab] OR ‘‘Item response 
model’’[tiab] OR IRT[tiab] OR Rasch[tiab] OR ‘‘Differential item functioning’’[tiab] OR DIF[tiab] 
OR ‘‘computer adaptive testing’’[tiab] OR ‘‘item bank’’[tiab] OR ‘‘cross-cultural equivalence’’[tiab]) 
 
EMBASE 
aphasia OR dysphasia AND stroke 
AND 
'intermethod comparison'/exp OR 'data collection method'/exp OR 'validation study'/exp OR 
'feasibility study'/exp OR 'pilot study'/exp OR 'psychometry'/exp OR 'reproducibility'/exp OR 
reproducib*:ab,ti OR 'audit':ab,ti OR psychometr*:ab,ti OR clinimetr*:ab,ti OR clinometr*:ab,ti OR 
'observer variation'/exp OR 'observer variation':ab,ti OR 'discriminant analysis'/exp OR 'validity'/exp 
OR reliab*:ab,ti OR valid*:ab,ti OR 'coefficient':ab,ti OR 'internal consistency':ab,ti OR 
(cronbach*:ab,ti AND ('alpha':ab,ti OR 'alphas':ab,ti)) OR 'item correlation':ab,ti OR 'item 
correlations':ab,ti OR 'item selection':ab,ti OR 'item selections':ab,ti OR 'item reduction':ab,ti OR 'item 
reductions':ab,ti OR 'agreement':ab,ti OR 'precision':ab,ti OR 'imprecision':ab,ti OR 'precise 
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values':ab,ti OR 'test-retest':ab,ti OR ('test':ab,ti AND 'retest':ab,ti) OR (reliab*:ab,ti AND ('test':ab,ti 
OR 'retest':ab,ti)) OR 'stability':ab,ti OR 'interrater':ab,ti OR 'inter-rater':ab,ti OR 'intrarater':ab,ti OR 
'intra-rater':ab,ti OR 'intertester':ab,ti OR 'inter-tester':ab,ti OR 'intratester':ab,ti OR 'intratester':ab,ti 
OR 'interobeserver':ab,ti OR 'inter-observer':ab,ti OR 'intraobserver':ab,ti OR 'intraobserver':ab,ti OR 
'intertechnician':ab,ti OR 'inter-technician':ab,ti OR 'intratechnician':ab,ti OR 'intratechnician':ab,ti OR 
'interexaminer':ab,ti OR 'inter-examiner':ab,ti OR 'intraexaminer':ab,ti OR 'intraexaminer':ab,ti OR 
'interassay':ab,ti OR 'inter-assay':ab,ti OR 'intraassay':ab,ti OR 'intra-assay':ab,ti OR 
'interindividual':ab,ti OR 'inter-individual':ab,ti OR 'intraindividual':ab,ti OR 'intra-individual':ab,ti 
OR 'interparticipant':ab,ti OR 'inter-participant':ab,ti OR 'intraparticipant':ab,ti OR 
'intraparticipant':ab,ti OR 'kappa':ab,ti OR 'kappas':ab,ti OR 'coefficient of variation':ab,ti OR 
repeatab*:ab,ti OR (replicab*:ab,ti OR 'repeated':ab,ti AND ('measure':ab,ti OR 'measures':ab,ti OR 
'findings':ab,ti OR 'result':ab,ti OR 'results':ab,ti OR 'test':ab,ti OR 'tests':ab,ti)) OR generaliza*:ab,ti 
OR generalisa*:ab,ti OR 'concordance':ab,ti OR ('intraclass':ab,ti AND correlation*:ab,ti) OR 
'discriminative':ab,ti OR 'known group':ab,ti OR 'factor analysis':ab,ti OR 'factor analyses':ab,ti OR 
'factor structure':ab,ti OR 'factor structures':ab,ti OR 'dimensionality':ab,ti OR subscale*:ab,ti OR 
'multitrait scaling analysis':ab,ti OR 'multitrait scaling analyses':ab,ti OR 'item discriminant':ab,ti OR 
'interscale correlation':ab,ti OR 'interscale correlations':ab,ti OR ('error':ab,ti OR 'errors':ab,ti AND 
(measure*:ab,ti OR correlat*:ab,ti OR evaluat*:ab,ti OR 'accuracy':ab,ti OR 'accurate':ab,ti OR 
'precision':ab,ti OR 'mean':ab,ti)) OR 'individual variability':ab,ti OR 'interval variability':ab,ti OR 
'rate variability':ab,ti OR 'variability analysis':ab,ti OR ('uncertainty':ab,ti AND ('measurement':ab,ti 
OR 'measuring':ab,ti)) OR 'standard error of measurement':ab,ti OR sensitiv*:ab,ti OR 
responsive*:ab,ti OR ('limit':ab,ti AND 'detection':ab,ti) OR 'minimal detectable concentration':ab,ti 
OR interpretab*:ab,ti OR (small*:ab,ti AND ('real':ab,ti OR 'detectable':ab,ti) AND ('change':ab,ti OR 
'difference':ab,ti)) OR 'meaningful change':ab,ti OR 'minimal important change':ab,ti OR 'minimal 
important difference':ab,ti OR 'minimally important change':ab,ti OR 'minimally important 
difference':ab,ti OR 'minimal detectable change':ab,ti OR 'minimal detectable difference':ab,ti OR 
'minimally detectable change':ab,ti OR 'minimally detectable difference':ab,ti OR 'minimal real 
change':ab,ti OR 'minimal real difference':ab,ti OR 'minimally real change':ab,ti OR 'minimally real 
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difference':ab,ti OR 'ceiling effect':ab,ti OR 'floor effect':ab,ti OR 'item response model':ab,ti OR 
'irt':ab,ti OR 'rasch':ab,ti OR 'differential item functioning':ab,ti OR 'dif':ab,ti OR 'computer adaptive 
testing':ab,ti OR 'item bank':ab,ti OR 'cross-cultural equivalence':ab,ti 
CINAHL 
aphasia OR dysphasia AND stroke 
AND 
TI psychometr* OR TI observer variation OR TI reproducib* OR TI reliab* OR TI unreliab* OR TI 
valid* OR TI coefficient OR TI homogeneity OR TI homogeneous OR TI “internal consistency” OR 
AB psychometr* OR AB observer variation OR AB reproducib* OR AB reliab* OR AB unreliab* 
OR AB valid* OR AB coefficient OR AB homogeneity OR AB homogeneous OR AB “internal 
consistency” OR (TI cronbach* OR AB cronbach* AND (TI alpha OR AB alpha OR TI alphas OR 
AB alphas)) OR (TI item OR AB item AND (TI correlation* OR AB correlation* OR TI selection* 
OR AB selection* OR TI reduction* OR AB reduction*)) OR TI agreement OR TI precision OR TI 
imprecision OR TI “precise values” OR TI test-retest OR AB agreement OR AB precision OR AB 
imprecision OR AB “precise values” OR AB test-retest OR (TI test OR AB test AND TI retest OR 
AB retest) OR (TI reliab* OR AB reliab* AND (TI test OR AB test OR TI retest or AB retest)) OR TI 
stability OR TI interrater OR TI interrater OR TI intrarater OR TI intra-rater OR TI intertester OR TI 
inter-tester OR TI intratester OR TI intra-tester OR TI interobserver OR TI inter-observer OR TI 
intraobserver OR TI intra-observer OR TI intertechnician OR TI inter-technician OR TI 
intratechnician OR TI intra-technician OR TI interexaminer OR TI inter-examiner OR TI 
intraexaminer OR TI intra-examiner OR TI interassay OR TI inter-assay OR TI intraassay OR TI 
intra-assay OR TI interindividual OR TI inter-individual OR TI intraindividual OR TI intra-individual 
OR TI interparticipant OR TI inter-participant OR TI intraparticipant OR TI intra-participant OR TI 
kappa OR TI kappa’s OR TI kappas OR TI repeatab* OR AB stability OR AB interrater OR AB 
inter-rater OR AB intrarater OR AB intra-rater OR AB intertester OR AB inter-tester OR AB 
intratester OR AB intra-tester OR AB interobserver OR AB inter-observer OR AB intraobserver OR 
AB intra-observer OR AB intertechnician OR AB inter-technician OR AB intratechnician OR AB 
intra-technician OR AB interexaminer OR AB inter-examiner OR AB intraexaminer OR AB intra-
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examiner OR AB interassay OR AB inter-assay OR AB intraassay OR AB intra-assay OR AB 
interindividual OR AB inter-individual OR AB intraindividual OR AB intra-individual OR AB 
interparticipant OR AB inter-participant OR AB intraparticipant OR AB intra-participant OR AB 
kappa OR AB kappa’s OR AB kappas OR AB repeatab* OR ((TI replicab* OR AB replicab* OR TI 
repeated OR AB repeated) AND (TI measure OR AB measure OR TI measures OR AB measures OR 
TI findings OR AB findings OR TI result OR AB result OR TI results OR AB results OR TI test OR 
AB test OR TI tests OR AB tests)) OR TI generaliza* OR TI generalisa* OR TI concordance OR AB 
generaliza* OR AB generalisa* OR AB concordance OR (TI intraclass OR AB intraclass AND TI 
correlation* or AB correlation*) OR TI discriminative OR TI “known group” OR TI factor analysis 
OR TI factor analyses OR TI dimension* OR TI subscale* OR AB discriminative OR AB “known 
group” OR AB factor analysis OR AB factor analyses OR AB dimension* OR AB subscale* OR (TI 
multitrait OR AB multitrait AND TI scaling OR AB scaling AND (TI analysis OR AB analysis OR TI 
analyses OR AB analyses)) OR TI item discriminant OR TI interscale correlation* OR TI error OR TI 
errors OR TI “individual variability” OR AB item discriminant OR AB interscale correlation* OR AB 
error OR AB errors OR AB “individual variability” OR (TI variability OR AB variability AND (TI 
analysis OR AB analysis OR TI values OR AB values)) OR (TI uncertainty OR AB uncertainty AND 
(TI measurement OR AB measurement OR TI measuring OR AB measuring)) OR TI “standard error 
of measurement” OR TI sensitiv* OR TI responsive* OR AB “standard error of measurement” OR 
AB sensitiv* OR AB responsive* OR ((TI minimal OR TI minimally OR TI clinical OR TI clinically 
OR AB minimal OR AB minimally OR AB clinical OR AB clinically) AND (TI important OR TI 
significant OR TI detectable OR AB important OR AB significant OR AB detectable) AND (TI 
change OR AB change OR TI difference OR AB difference)) OR (TI small* OR AB small* AND (TI 
real OR AB real OR TI detectable OR AB detectable) AND (TI change OR AB change OR TI 
difference OR AB difference)) OR TI meaningful change OR TI “ceiling effect” OR TI “floor effect” 
OR TI “Item response model” OR TI IRT OR TI Rasch OR TI “Differential item functioning” OR TI 
DIF OR TI “computer adaptive testing” OR TI “item bank” OR TI “cross-cultural equivalence” OR 
TI outcome assessment OR AB meaningful change OR AB “ceiling effect” OR AB “floor effect” OR 
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AB “Item response model” OR AB IRT OR AB Rasch OR AB “Differential item functioning” OR 
AB DIF OR AB “computer ad 
 
 
 
 
 
 
 
